Amryt Pharma plc (LON:AMYT – Get Rating)’s stock price passed below its 50 day moving average during trading on Wednesday . The stock has a 50 day moving average of GBX 143 ($1.74) and traded as low as GBX 143 ($1.74). Amryt Pharma shares last traded at GBX 143 ($1.74), with a volume of 90,727 shares traded.
Amryt Pharma Stock Down 11.7 %
The company has a debt-to-equity ratio of 66.05, a current ratio of 1.80 and a quick ratio of 1.14. The company has a market capitalization of £457.11 million and a PE ratio of -4.33. The business has a 50-day moving average of GBX 143 and a 200 day moving average of GBX 143.
Amryt Pharma Company Profile
Amryt Pharma plc, a commercial-stage biopharmaceutical company, develops and commercializes novel therapeutics to treat patients suffering from serious and life-threatening rare diseases. The company offers Lomitapide for the treatment of homozygous familial hypercholesterolemia; and Metreleptin for the treatment of generalized and partial lipodystrophy.
Read More
- Meta Platforms: Efficiency Gains Momentum, Stock Accelerates
- Pfizer’s Latest Acquisition Strengthens the Case for PFE Stock
- SentinelOne: Reversal In-Play For Cybersecurity Stocks
- Is Sportradar Group A Growth Stock To Bet On In 2023?
- Strong Guidance says Boeing is Ready for Takeoff
Receive News & Ratings for Amryt Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amryt Pharma and related companies with MarketBeat.com's FREE daily email newsletter.